CFT7455

CFT7455 is an orally bioavailable MonoDAC™ degrader (or monofunctional degradation activating compound) of IKZF1 (Ikaros) and IKZF3 (Aiolos) currently in a Phase 1/2 clinical trial for the treatment of multiple myeloma and non-Hodgkin’s lymphomas. We designed CFT7455 to bind with high affinity to the E3 ligase adapter protein, Cereblon, to target and degrade IKZF1/3, key proteins for multiple myeloma and non-Hodgkin’s lymphomas. In early clinical data, CFT7455 demonstrated deep and durable degradation of IKZF1/3.

Opportunity for Targeted Protein Degradation

IKZF1/3 are transcription factors required for cancer cell growth and survival in multiple myeloma and non-Hodgkin’s lymphomas. However, transcription factors do not have an active site binding pocket; this means inhibitors cannot target these important proteins. Rather, degraders are the only therapeutic approach. Today, approved IKZF1/3 degraders (lenalidomide and pomalidomide) are widely used in multiple myeloma treatment, but there remains a high unmet medical need for therapies to treat relapsed/refractory multiple myeloma.

Scientific Presentations and Publications

CFT7455: A novel IKZF1/3 degrader, demonstrates potent anti-tumor activity in peripheral and CNS models of non-Hodgkin’s lymphoma as a single agent or in combination with clinically approved agents

The Discovery and Characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma

AACR Poster Presentation: CFT7455 Phase 1/2 Cohort A

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

CFT7455: A novel, IKZF1/3 Degrader That Demonstrates Potent Tumor Regression in a Spectrum of Non-Hodgkin Lymphoma Xenograft Models

CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models